Bo Kara - Mereo BioPharma Senior CMC
| MREO Stock | USD 3.56 0.16 4.71% |
Executive
Bo Kara is Senior CMC of Mereo BioPharma Group
| Address | One Cavendish Place, London, United Kingdom, W1G 0QF |
| Phone | 44 33 3023 7300 |
| Web | https://www.mereobiopharma.com |
Mereo BioPharma Management Efficiency
The company has return on total asset (ROA) of (0.2386) % which means that it has lost $0.2386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4847) %, meaning that it created substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of December 2024, Return On Tangible Assets is likely to drop to -0.47. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Mereo BioPharma's Total Assets are very stable compared to the past year. As of the 18th of December 2024, Net Tangible Assets is likely to grow to about 45.6 M, while Non Current Assets Total are likely to drop about 2.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Courtney | Hookipa Pharma | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| MS MBA | PDS Biotechnology Corp | 58 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Kirk MD | PDS Biotechnology Corp | 72 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Lars MBA | PDS Biotechnology Corp | 54 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Roman Necina | Hookipa Pharma | 56 | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Mark Winderlich | Hookipa Pharma | 38 | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.24 |
Mereo BioPharma Group Leadership Team
Elected by the shareholders, the Mereo BioPharma's board of directors comprises two types of representatives: Mereo BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mereo. The board's role is to monitor Mereo BioPharma's management team and ensure that shareholders' interests are well served. Mereo BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mereo BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine CPA, Chief Officer | ||
| Bo Kara, Senior CMC | ||
| Fiona Bor, Head Property | ||
| Charles Sermon, Co-Founder, General Counsel, Secretary | ||
| Jackie Parkin, Therapy Endocrinology | ||
| MBBS MD, CoFounder Strategy | ||
| John Lewicki, Chief Officer | ||
| Alexandra HughesWilson, Chief Planning | ||
| John MBA, CoFounder Officer | ||
| Denise ScotsKnight, CEO, Co-Founder, Executive Director | ||
| Suba Krishnan, Senior Development | ||
| MBA MBA, CoFounder Officer |
Mereo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mereo BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (37.90) % | ||||
| Current Valuation | 453.65 M | ||||
| Shares Outstanding | 153.85 M | ||||
| Shares Owned By Insiders | 1.02 % | ||||
| Shares Owned By Institutions | 65.66 % | ||||
| Number Of Shares Shorted | 6.63 M | ||||
| Price To Earning | 6.73 X | ||||
| Price To Book | 7.38 X |
Pair Trading with Mereo BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Mereo Stock
Moving against Mereo Stock
| 0.73 | DYAI | Dyadic International | PairCorr |
| 0.66 | BMY | Bristol Myers Squibb | PairCorr |
| 0.56 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.48 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 0.007 | Return On Assets (0.24) | Return On Equity (0.48) |
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.